LAMA3 DNA methylation and transcriptome changes associated with chemotherapy resistance in ovarian cancer

被引:0
作者
Li-yuan Feng
Yong-zhi Huang
Wei Zhang
Li Li
机构
[1] Guangxi Medical University Cancer Hospital,Department of Gynecologic Oncology
[2] Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor,undefined
[3] Ministry of Education,undefined
来源
Journal of Ovarian Research | / 14卷
关键词
Ovarian cancer; Chemoresistance ; LAMA3 methylation; Prognosis;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 110 条
[11]  
Sharifi M(2016)Transcription factors as readers and effectors of DNA methylation [J] Nat Rev Genet 17 551-565
[12]  
Jiang X(2019)Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer [J] Clin Epigenetics 11 153-330
[13]  
Li X(2017)DNA methylation and Transcriptome Changes Associated with Cisplatin Resistance in Ovarian Cancer [J] Sci Rep 7 1469-169
[14]  
Li W(2019)Methylation and ovarian cancer: Can DNA methylation be of diagnostic use?[J] Mol Clin Oncol 10 323-3785
[15]  
van Zyl B(2019)Hypermethylation of tumor suppressor genes is a risk factor for poor prognosis in ovarian cancer: A meta-analysis [J] Medicine (Baltimore) 98 160-2293
[16]  
Tang D(2018)Epigenetics in ovarian cancer [J] Semin Cancer Biol 51 3775-644
[17]  
Bowden NA(2020)Epigenetic Attire in Ovarian Cancer: The Emperor's New Clothes [J] Cancer Res 80 7-599
[18]  
Christie EL(2019)Epigenetic therapy for ovarian cancer: promise and progress [J] Clin Epigenetics 11 2285-182
[19]  
Bowtell DDL(2018)A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses [J] Clin Cancer Res 24 631-2818
[20]  
Freimund AE(2017)The safety, efficacy, and treatment outcomes of a combination of low-dose decitabine treatment in patients with recurrent ovarian cancer [J] Oncoimmunology 6 214-296